|
Effects of recombinant human brain natriuretic peptide combined with sacubatril valsartan sodium tablets on ventricular remodeling and cardiac function of pationts with acute myocardial infarction and heart failure |
Received:July 21, 2021 |
View Full Text View/Add Comment Download reader |
DOI:10.11915/j.issn.1671-5403.2022.04.059 |
Key words:recombinant human brain natriuretic peptide sacubitril valsartan sodium tablets acute myocardial infarction heart failure Corresponding author:LI Zhen, E-mail:lizhenshandong68@163.com〖FL |
|
Hits: 195 |
Download times: 104 |
Abstract: |
Objective To investigate the effects of recombinant human brain natriuretic peptide (rhBNP) combined with sacubitril valsartan sodium tablets on ventricular remodeling and cardiac function of patients with acute myocardial infarction and heart failure. Methods A total of 60 patients with acute ST-segment elevation myocardial infarction complicated with heart failure admitted to our department from May 2019 to May 2021 were prospectively recruited in the clinical trial. They were randomly divided into control and observation groups, with 30 patients in each group. The control group was treated with rhBNP alone. The observation group was treated with rhBNP+sacubitril valsartan sodium tablets. Other anti-heart failure measures were the same in the 2 groups. After 1 month of treatment, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, and 6-minute walking distance (6MWD) were compared between the 2 groups. SPSS statistics 19.0 was used for statistical analysis. Data comparison between 2 groups was conducted using student′s t test, rank sum test or Chi-square test depending on data types. Results After 1 month of treatment, LVEDD and LVESD were decreased and LVEF was increased in both groups when compared with those before treatment (P<0.05). The levels of LVEDD [(42.25±4.28) vs (48.61±4.47) mm] and LVESD[(38.60±4.06) vs (44.20±4.15)mm] were significantly lower, and that of LVEF [(49.25±4.19)% vs (44.38±3.87)%] was obviously higher in the observation group than the control group (all P<0.05). The treatments also resulted in statistically lower NT-proBNP level [(353.15±66.23) vs (389.46±54.21) pg/ml] and longer 6MWD [(441.17±32.18) vs (334.76±31.16) m] in the observation group than the control group (both P<0.05). Conclusion RhBNP combined with sacubitril valsartan sodium tablets can effectively improve the cardiac function and reversal of ventricular remodeling of acute myocardial infarction patients complicated with heart failure. |
Close |
|
|
|